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Abstract Objective: To study
whether selective decontamination
of the digestive tract (SDD) results
in detectable serum tobramycin con-
centrations in intensive care unit
(ICU) patients with acute renal failure
treated with continuous venovenous
hemoﬁltration (CVVH). Design and
setting: Prospective, observational,
single-center study in a mixed med-
ical–surgical ICU. Patients: Adult
ICU patients receiving SDD for at
least 3 days and being treated with
CVVH because of acute renal failure.
Measurements and results: Tobra-
mycin serum concentrations were
measured at the 3rd day after start
of CVVH and every 3 days thereafter.
Detectable serum concentrations of
tobramycin were found in 12 (63%)
of 19 patients and in 15 (58%) of the
26 samples. With a toxic tobramycin
concentration deﬁned as more than
2.0mg/l, we found one patient with
a toxic concentration of 3.0mg/l.
In three other patients tobramycin
concentrations of ≥1.0mg/l were
found. Conclusions: In patients
with acute renal failure treated with
CVVH, administration of SDD with
tobramycin can lead to detectable and
potentially toxic serum tobramycin
concentrations.
Introduction
Selective decontamination of the digestive tract (SDD)
is an infection-prophylaxis regimen in intensive care
unit (ICU) patients, aiming at eradicating the potentially
pathogenic micro-organisms from the mouth and stomach,
while preserving the intestinal anaerobic ﬂora to prevent
overgrowth with resistant bacteria and yeasts. Most
SDD regimens use the combination of topically applied
tobramycin, colistin and amphotericin B. These antibiotics
are given topically in the mouth and through a gastric tube
in the stomach four times daily. Some regimens combine
this local therapy with systemic antibiotic prophylaxis for
the ﬁrst couple of days. All three of the topical antibiotics
mentioned above are regarded as non-absorbable and
therefore safe [1].
After prolonged use, however, minimal enteral absorp-
tion of tobramycin might lead to potentially toxic serum
concentrationsin patients with impaired renal function [2].
Normally, more than 90% of tobramycin is eliminated by
glomerular ﬁltration. Renal replacement therapy by con-
tinuous venovenous hemoﬁltration (CVVH) leads to only
limited drug clearance [3]. Thus, ICU patients with renal
failure are at highest risk of developing toxic serum con-
centrations of tobramycin after enteral administration.
Serum concentrations of tobramycin are commonly
monitored to minimize the risk of toxicity after systemic
administration, aiming at a trough concentration of less
than 2.0mg/l [2].
The aim of this study was to determine whether enteral
administration of tobramycin as part of the SDD regimen
can lead to detectable and potentially toxic serum concen-904
trations in ICU patients with acute renal failure requiring
CVVH.
Materials and methods
Study design
We conducted a prospective single-center observational
study. From June 2006 to October 2006, all eligible
patients were included in the study. Eligible patients
were older than 18 years, admitted to our 28-bed mixed
medical–surgical ICU, receiving SDD and treated with
CVVH. Patients with systemic use of tobramycin or
another aminoglycoside within the previous 5 days were
excluded from the study.
Because the study involved no interventions, and be-
cause measuring serum tobramycin concentrations in pa-
Table 1 Patient characteristics
Patient Age Sex Weight APACHE II SOFA Creat. Diuresis Days Diagnosis
(years) (male/female) (kg) start CVVH (ml/h) CVVH
1 59 M 90 18 12 284 29 9 Cardiac shock
with ARDS
2 42 M 100 22 16 287 6 3 Necrotizing fasciitis
and ischemic large bowel
3 44 M 85 8 13 124 2,5 6 Abdominal sepsis
4 68 F 56 36 15 367 25 3 Decompensated liver cirrhosis
5 36 F 75 23 8 318 5 3 Fluxus postpartum
6 77 M 75 23 9 131 17 6 Cardiac shock after
acute myocardial infarct
7 83 M 75 37 14 180 5 6 Out of hospital
cardiac arrest
8 68 M 90 29 14 244 12 10 Septic shock caused
by necrotic pancreatitis
9 51 F 70 23 17 422 0 6 Medication induced
liver failure
10 72 M 84 27 12 265 31 5 Complicated cardiac
surgery
11 56 M 99 25 11 260 25 8 Postoperative after
thymectomy
12 66 F 70 20 7 143 67 2 Cardiac and mesenteric
ischemia
13 61 M 80 26 13 327 13 4 Intra-abdominal arterial
bleeding
14 55 F 74 31 15 243 3 9 Abdominal sepsis caused
by fecal peritonitis
15 74 F 65 18 13 84 25 3 Abdominal sepsis caused
by ischemia from the small bowel
16 72 M 73 25 11 614 0 3 Respiratory failure caused
by ﬂuid overload
17 61 F 58 22 13 162 26 9 Cardiac shock after massive
acute myocardial infarct
18 54 M 95 15 12 157 59 6 Respiratory failure caused
by pneumonia
19 72 M 80 22 14 136 108 6 Cardiac shock caused by mitral
valve insufﬁciency due to acute
myocardial infarct
APACHE II, APACHE II score on the day of admission to ICU; SOFA, SOFA score on day of admission to ICU; Diuresis, urine production
(ml/h) in the last 24h before starting CVVH; Days CVVH, number of days on CVVH at time ﬁrst blood sample was drawn
tients on CVVH was part of routine patient care, the local
medicalethics reviewboardwaivedthe requirementfor in-
formed consent.
The SDD regimen consisted of four times daily treat-
ment with approximately 0.5g of a paste, applied to the
oral cavity, containing 2% colistin, 2% tobramycin, and
2% amphotericin B. Patients also received 100mg colistin
sulfate, 80mg tobramycin, and 500mg amphotericin B
administered through a gastric tube four times daily. Pa-
tients with blind loops (e.g., after colostomy) additionally
received suppositories containing 42mg amphotericin B,
42mg colistin sulfate, and 64mg tobramycin (as sulfate).
Initiation of CVVH in our department is considered in
patients who are oliguric despite adequate ﬂuid resusci-
tation and/or display a persistent steep rise in plasma crea-
tinine in addition to persistent shock. Vascular access was
obtained by insertion of a double-lumen catheter (Duo-
Flow400XL,14F×6 in.(15cm);Medcomp,Harleysville,905
PA, USA) into a large vein (femoral, subclavian, or inter-
nal jugular vein). CVVH was performed using a Diapact
hemoﬁltration machine (B. Braun Melsungen, Melsungen,
Germany) and a cellulose triacetate hemoﬁlter (CT-190G;
Baxter Healthcare, Deerﬁeld, IL, USA). The ultraﬁltration
rate was set at 35ml/kg/h.
Blood samples for the measurement of tobramycin
concentrations were scheduled for the 3rd day after start
of CVVH and every 3 days thereafter. Patients had to have
received SDD for at least 3 days.
Given the slow absorption and elimination of to-
bramycin and the frequent (four times daily) dosing,
tobramycin concentrations were assumed to be steady
state, and serum samples were taken randomly (not as
trough or peak concentrations).
Tobramycin concentrations were determined with
a validated ﬂuorescence polarization immunoassay (FPIA;
Axsym®, Abbott Laboratories, IL, USA). The lower limit
of determination using this technique is 0.2mg/l. Toxic
serum concentrations of tobramycin were deﬁned as more
than 2.0mg/l [2].
Results
A total of 26 samples were obtained from 19 patients.
Baseline characteristics of the patients included are shown
Patient SDD (orally and SDD Days Tobramycin serum
via gastric tube) suppositories on SDD concentrations (mg/l)
1+ – 2 4 <0.2
+ – 27 0.2
2+ – 3 0 . 2
+– 6 1 . 1
+ – 10 1.7
3+ + 6 0 . 5
++ 9 0 . 5
4+ – 3 0 . 2
5+ – 3 <0.2
6+ – 1 9 <0.2
7+ – 6 <0.2
8+ – 9 0 . 7
9+ – 6 0 . 3
10 + – 6 0.2
11 + – 6 <0.2
12 + – 3 3.0
13 + – 3 0.2
14 + + 9 <0.2
15 + + 3 1.1
16 + – 3 <0.2
+– 6 0 . 3
17 + – 7 <0.2
+– 9 <0.2
18 + – 6 <0.2
+– 9 <0.2
19 + – 6 1.0
<0.2: below quantiﬁcation limit
Table 2 Treatment with SDD
and tobramycin serum
concentrations
in Table1. Patients were treated with CVVH for median
6 days (interquartile range, IQR, 3–8 days). Serum con-
centrations of tobramycin and the doses of SDD admin-
istered are shown in Table2. Patients were treated with
SDD for median 6 days (IQR 3–9 days). Three patients
received SDD suppositories as additional prophylaxis.
Detectable serum concentrations were found in 12
(63%) of 19 patients and in 15 (58%) of the 26 samples.
We found one patient with a toxic concentration of
3.0mg/l. In three other patients tobramycin concentrations
of ≥1.0mg/l were found.
The three patients with highest tobramycin concentra-
tions all had ischemic bowel disease. In contrast, no pa-
tients with concentrations<1 mg/l had intestinal ischemia
(Table1).
In six patients more than one sample was drawn. In
three of them, consecutive samples showed a rise in con-
centration with prolonged SDD use. One patient showed
a tobramycin concentration of 1.1mg/l after 6 days of
CVVH, rising to 1.7mg/l 4 days later.
Discussion
We show that in ICU patients receiving enteric tobramycin
as part of SDD, detectable serum concentrations of
tobramycin are found in more than half of patients with906
acute renal failure treated with CVVH. We found one
patient with a toxic serum concentration of tobramycin.
These ﬁndings are in contrast to the general belief that
tobramycin is not absorbed from the gastrointestinal tract
and that SDD may be safely used in all patients [4].
Our ﬁndings, however, are supported by two pre-
vious reports. In 1991 Gastinne et al. measured serum
tobramycin concentrations in 15 mechanically ventilated
ICU patients on SDD. Detectable tobramycin concentra-
tions were found in 9 patients and in 50% of the serum
samples. In two patients with renal failure, toxic serum
concentrations> 2.0mg/l were found[5]. In a more recent
investigation, Camus also reported systemic tobramycin
concentrations exceeding 2mg/l using SDD. In their study
comparing two different decontamination regimens, they
found toxic tobramycin serum concentrations in 21 of 74
(28%) patients. In all these patients creatinine clearance
was < 30ml/min [6].
Toxicity of tobramycin includes nephrotoxicity and
ototoxicity, which may be seen respectively in 10–20%
and 10% of the patients with serum trough concentra-
tions> 2.0mg/l [2]. However, accumulation of tobramy-
cin in renal cortical cells is seen even when trough con-
centrations do not exceed this limit, potentially resulting
in damage to proximal tubuli [7]. Thus, it cannot be ex-
cluded that prolonged detectable serum concentrations of
tobramycin are toxic even if lower than 2.0mg/l.
The major limitation of our study is its small size. Fur-
thermore, we only studied patients with acute renal failure
requiring CVVH. Tobramycin clearance by CVVH may
be approximately 80% of ultraﬁltrate rate (35ml/h in our
study) [8]. In patients with renal failure not treated with re-
nal replacement therapy, the likelihood of accumulation of
tobramycininserummaybeevenhigher.Althoughtherisk
oftoxicserumconcentrationswillbelowerinpatientswith
no major impairment of renal function, prolonged use of
SDD may lead to detectable serum tobramycin concentra-
tionsin thesepatientstoo [2,5, 6].We did notstudyfactors
that inﬂuence the enteric absorption of tobramycin. It may
be hypothesized that tobramycin absorption is higher in
patients with a decreased gut barrier function. Indeed, in-
creased absorption of polyethylene glycol has been shown
in patients with inﬂammatory bowel disease [9]. In normal
conditions enteral absorption of tobramycin in humans is
very low due to active efﬂux of the drug by P-glycoprotein
in the brush border of the intestinal mucosa [10]. If the
intestinal mucosa is damaged for any reason, this efﬂux
pump may not function optimally and tobramycin absorp-
tion is then increased. Interestingly, in our study the high-
est tobramycin concentrations were exclusively found in
patients with intestinal ischemia.
In conclusion, administration of SDD can lead to de-
tectable and potentially toxic serum concentrations of to-
bramycin in patients with renal failure. More studies are
needed to identify factors related to increased enteral ab-
sorption of tobramycin. We recommend determination of
plasma concentrations of tobramycin in all ICU patients
with severely impaired renal function and on prolonged
treatment with SDD.
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